[go: up one dir, main page]

WO2008008852A3 - Cxcr4 antagonists including heteroatoms for the treatment of medical disorders - Google Patents

Cxcr4 antagonists including heteroatoms for the treatment of medical disorders Download PDF

Info

Publication number
WO2008008852A3
WO2008008852A3 PCT/US2007/073282 US2007073282W WO2008008852A3 WO 2008008852 A3 WO2008008852 A3 WO 2008008852A3 US 2007073282 W US2007073282 W US 2007073282W WO 2008008852 A3 WO2008008852 A3 WO 2008008852A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
compounds
medical disorders
antagonists including
cxcr4 antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/073282
Other languages
French (fr)
Other versions
WO2008008852A2 (en
Inventor
Dennis C Liotta
James P Snyder
Weiqiang Zhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of WO2008008852A2 publication Critical patent/WO2008008852A2/en
Publication of WO2008008852A3 publication Critical patent/WO2008008852A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides compounds, pharmaceutical compositions and methods of use of certain compounds that are antagonists of the chemokine CXCR4 receptor for the treatment of proliferative conditions mediated by CXCR4 receptors. Certain compounds provided can interfere with the binding of SDFl to the receptor. These compounds are particularly useful for treating or reducing the severity of hyperproliferative diseases by inhibiting metastasis. The compounds provided can also be useful for the treatment or prophylaxis of an HIV infection in a host.
PCT/US2007/073282 2006-07-11 2007-07-11 Cxcr4 antagonists including heteroatoms for the treatment of medical disorders Ceased WO2008008852A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83000506P 2006-07-11 2006-07-11
US60/830,005 2006-07-11
US81998607P 2007-07-11 2007-07-11
US60/819,986 2007-07-11

Publications (2)

Publication Number Publication Date
WO2008008852A2 WO2008008852A2 (en) 2008-01-17
WO2008008852A3 true WO2008008852A3 (en) 2008-11-20

Family

ID=38924157

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/073282 Ceased WO2008008852A2 (en) 2006-07-11 2007-07-11 Cxcr4 antagonists including heteroatoms for the treatment of medical disorders

Country Status (1)

Country Link
WO (1) WO2008008852A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
US9296701B2 (en) 2012-04-24 2016-03-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9340557B2 (en) 2013-03-12 2016-05-17 Vertex Pharmaceuticals Incorporated Substituted quinoxaline DNA-PK inhibitors

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010010619A (en) 2008-03-28 2010-12-17 Altiris Therapeutics Chemokine receptor modulators.
EP2476441A1 (en) 2011-01-13 2012-07-18 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
SI2794626T1 (en) 2011-12-22 2018-02-28 Glycomimetics, Inc. E-selectin antagonist compounds
AU2013355238B2 (en) 2012-12-07 2017-12-14 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
RU2675270C2 (en) 2013-10-17 2018-12-18 Вертекс Фармасьютикалз Инкорпорейтед Co-crystals and pharmaceutical compositions containing same
EP3227310B1 (en) 2014-12-03 2019-07-31 GlycoMimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TWI773657B (en) 2015-12-18 2022-08-11 美商亞德利克斯公司 Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
EP3497131B1 (en) 2016-08-08 2022-03-09 GlycoMimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4.
WO2018064092A1 (en) 2016-09-27 2018-04-05 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
CA3037850A1 (en) 2016-10-07 2018-04-12 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
WO2018081167A1 (en) 2016-10-24 2018-05-03 Yumanity Therapeutics Compounds and uses thereof
IL304017A (en) 2017-01-06 2023-08-01 Yumanity Therapeutics Inc Methods for the treatment of neurological disorders
EP3596096A1 (en) 2017-03-15 2020-01-22 GlycoMimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
EP3700934A4 (en) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
JP7275131B2 (en) 2017-11-30 2023-05-17 グリコミメティクス， インコーポレイテッド Methods of mobilizing bone marrow-infiltrating lymphocytes and uses thereof
CN111566117A (en) 2017-12-29 2020-08-21 糖模拟物有限公司 Heterobifunctional inhibitors of E-selectin and galectin-3
WO2019173229A1 (en) 2018-03-05 2019-09-12 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
SG11202009280RA (en) 2018-03-23 2020-10-29 Yumanity Therapeutics Inc Compounds and uses thereof
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
SG11202108079RA (en) 2019-01-24 2021-08-30 Yumanity Therapeutics Inc Compounds and uses thereof
MA55385A (en) * 2019-03-22 2022-01-26 Yumanity Therapeutics Inc COMPOUNDS AND THEIR USES
EA202192047A1 (en) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074428A2 (en) * 2005-01-07 2006-07-13 Emory University Cxcr4 antagonists for the treatment of medical disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074428A2 (en) * 2005-01-07 2006-07-13 Emory University Cxcr4 antagonists for the treatment of medical disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] KAWAMURA ET AL.: "Preparation of novel substituted fused imidazole derivatives.....", Database accession no. (144:292780) *
KING F.D.: "Bioisosteres, Conformational Restriction, and Pro-drugs-Case History: An Example of a Conformational Restriction Approach", MEDICINAL CHEMISTRY: PRINCIPLES AND PRACTICE, 1994, pages 206 - 209, XP002914319 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
US9296701B2 (en) 2012-04-24 2016-03-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9376448B2 (en) 2012-04-24 2016-06-28 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9592232B2 (en) 2012-04-24 2017-03-14 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9340557B2 (en) 2013-03-12 2016-05-17 Vertex Pharmaceuticals Incorporated Substituted quinoxaline DNA-PK inhibitors
US9359380B2 (en) 2013-03-12 2016-06-07 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors

Also Published As

Publication number Publication date
WO2008008852A2 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
WO2008008852A3 (en) Cxcr4 antagonists including heteroatoms for the treatment of medical disorders
WO2006074428A3 (en) Cxcr4 antagonists for the treatment of medical disorders
WO2008008854A3 (en) Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders
MY145349A (en) Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor
MX2009008787A (en) 2-aminopyrimidine modulators of the histamine h4 receptor.
EP2004188A4 (en) Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor
WO2010008831A3 (en) Compounds and methods for modulating g protein-coupled receptors
UA95949C2 (en) Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
WO2009082038A3 (en) Ampa receptor antagonists and zonisamide for epilepsy
TN2011000171A1 (en) Isonicotinamide orexin receptor antagonists
IN2012DN02735A (en)
IN2012DN00754A (en)
MY158927A (en) Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor
JO2645B1 (en) Compounds
WO2008021375A3 (en) Modulators of muscarinic receptors
WO2007100664A3 (en) Modulators of muscarinic receptors
WO2007146073A3 (en) Method for enhancing cognitive function
WO2009128661A3 (en) A novel benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof
WO2009156680A3 (en) Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders
WO2009067607A3 (en) Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
AU2014287427B2 (en) Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist
WO2006131874A3 (en) Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
GB0611907D0 (en) Compounds
WO2007131041A3 (en) The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2
WO2008094574A3 (en) Furanone compounds and methods of making and using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07799499

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07799499

Country of ref document: EP

Kind code of ref document: A2